Oxford Club’s seminar on Biosimilar drugs
by radesrochers | May 29, 2015 9:58 pm
Guys, I just listened to the Oxford Clubs ”seminar” on the impending surge in the use of Biosimilar drugs in the US. They want you to subscribe to a newsletter and will give you the five ”best” stocks to retire on if you pay the price. Does anyone have any idea what they are as well as any thoughts about how rewarding they may become?
Source URL: https://www.stockgumshoe.com/2015/05/microblog-oxford-clubs-seminar-on-biosimilar-drugs/
I do not know the right answer for your question, but I read a teaser from Paul Mampily’s research: “He’s also shared another company with a powerful medical database. It’s so valuable that Wal-Mart pays an estimated $6 million a year to allow its employees access. Other big companies are doing the same, including Kraft and CVS Health.” Does anyone have a clue that which company is it? I have not found anything about it. Thank you for your help in advance.
I hate to go off subject but this company has been in business five years looking for cfo lithium is a projected to grow so much we can not handle it all the website is SMARTBATTARY.com take a look are customers include nasa fm us navy coastguard army looking for equity partner To come in already been contacted by shark tank but we need a full time cfo or ceo sorry again but if anybody could point us in right direction really be thankful lot of money to be made
A couple biosimilar equities that our Irregular super-sleuth, Glenn mentioned are:
MNTA-Momenta Pharmaceuticals, Inc. is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. The Company’s approach is built around a complex systems analysis platform that it uses to obtain a detailed understanding of complex chemical and biologic systems, design product candidates, analyze sets of biological data to evaluate the biological function of its products and develop manufacturing processes that enable its products to be reliably produced. The Company uses its complex systems analysis platform to define the detailed structures present in these complex drugs. To demonstrate that the biological function of the Company’s generic replicates that of the brand, the Company utilizes its complex systems analysis platform to evaluate and compare multiple orthogonal sets of biologic data from in-vitro, in-vivo and ex-vivo models.
and
PFNX-Pfenex Inc. is a clinical-stage biotechnology Company. The Company is engaged in the development of difficult to manufacture and high-value proteins, initially focused on biosimilar therapeutics. The Company’s core technology, Pfenex Expression Technology for recombinant protein expression, is able to rapidly develop and produce high quality therapeutics. The Company’s Pfenex Expression Technology combines a toolbox of expression components with a robotically enabled high-throughput parallel strain screening technology, delivering speed and success in identifying protein production strains expressing high titers of soluble, active protein. The Company’s lead product candidate is PF582, a biosimilar candidate. It is used for the treatment of retinal diseases. The Company’s other product candidate is PF530, is for the treatment of multiple sclerosis. The Company is developing Px563L, an anthrax vaccine candidate.
Thanks Glenn! Best2ALL-Benjamin
I am interested in investing in a stock that covers Pinpoint Surgery. Do any of you know what stock this is?